BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018
Net Income	-2.63	-0.36	0.75	1.09	-0.25	0.03
Depreciation & Amortization	0.11	0.11	0.11	0.1	0.05	0.04
Share-Based Compensation	0.51	0	0	0	0	0
Other Operating Activities	0.71	0.79	-0.85	-0.64	-0.02	-0.34
Operating Cash Flow	-1.3	0.54	0.01	0.55	-0.22	-0.27
Operating Cash Flow Growth	-	5838.52%	-98.34%	-	-	-
Capital Expenditures	-0.15	-0.05	-0	-0.42	-0.01	-0.04
Acquisitions	0.47	0	0	0.35	0	0
Change in Investments	-0.35	-0.51	-0.52	-0.14	-	-0.01
Other Investing Activities	-0.36	0.12	0.03	1.53	-	-
Investing Cash Flow	-0.38	-0.45	-0.49	1.32	-0.01	-0.05
Common Stock Issued	5.75	0.15	0	0	0	0
Other Financing Activities	0	-0.03	-0.03	-0	-0.18	0.74
Financing Cash Flow	5.75	0.12	-0.03	-0	-0.18	0.74
Net Cash Flow	3.81	-0.01	-0.66	1.93	-0.4	0.42
Free Cash Flow	-1.45	0.49	0.01	0.13	-0.23	-0.31
Free Cash Flow Growth	-	8065.64%	-95.42%	-	-	-
Free Cash Flow Margin	-14.85%	4.48%	0.04%	1.15%	-181.24%	-147.74%
Free Cash Flow Per Share	-0.09	0.03	0.00	0.02	-0.03	-0.06

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.